OPKO HEALTH, INC. (OPK) - Dilution Analysis

10-Q filing | 758.9M shares outstanding

10-Q filing | 777.2M shares outstanding

10-Q filing | 788.0M shares outstanding

10-Q filing | 793.1M shares outstanding

8-K filing: OPKO Health, Inc. completed an exchange of $159,221,000 aggregate principal amount of Notes for 121,437,998 shares of Common Stock and approximately $63.5 million in cash.

8-K filing: OPKO Health, Inc. exchanged $152,471,000 aggregate principal amount of Notes for an aggregate of 116,706,310 shares of the Company's common stock and approximately $60.1 million in cash with certain institutional holders on March 27, 2025.

10-K filing | 694.0M shares outstanding

10-Q filing | 694.6M shares outstanding

10-Q filing | 697.2M shares outstanding

10-Q filing | 706.9M shares outstanding

10-K filing | 751.8M shares outstanding

8-K filing: OPKO Health, Inc. terminated its share lending agreement with Jefferies Capital Services, LLC, and all approximately 30 million borrowed shares were returned to the Company to be held as treasury shares.

10-Q filing | 751.5M shares outstanding

10-Q filing | 751.7M shares outstanding

10-Q filing | 751.5M shares outstanding

10-K filing | 719.1M shares outstanding

10-Q filing | 750.4M shares outstanding

10-Q filing | 712.5M shares outstanding

8-K filing: OPKO Health, Inc. issued 89,907,310 shares of its common stock to the former stockholders of ModeX Therapeutics, Inc. as consideration for the acquisition of ModeX. ($300.0M proceeds)

10-Q filing | 660.3M shares outstanding

8-K filing: OPKO Health, Inc. completed the merger with Sema4 Holdings Corp. on April 29, 2022, receiving $150.0 million in cash and 80.0 million shares of Sema4's Class A common stock for GeneDx. ($150.0M proceeds)

10-K filing | 648.1M shares outstanding

8-K filing: OPKO Health, Inc. entered into an Agreement and Plan of Merger and Reorganization with Sema4 Holdings Corp., its two wholly owned subsidiaries, GeneDx Inc., and GeneDx Holding 2, Inc., where Sema4 will pay OPKO $150.0 million in cash and 80.0 million shares of Sema4's Class A common stock for GeneDx.

10-Q filing | 651.8M shares outstanding

10-Q filing | 647.0M shares outstanding

8-K filing: OPKO Health, Inc. entered into an Exclusive License Agreement with CAMP4 Therapeutics Corporation, granting CAMP4 an exclusive license to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology. OPKO will receive an upfront payment of $1.5 million and 3,373,008 shares of CAMP4's Series A Prime Preferred Stock, which equates to approximately 5% of the outstanding shares of CAMP4.

8-K filing: The company issued 19,051,270 shares of common stock in exchange for $55.42 million in aggregate principal amount of 4.50% Convertible Senior Notes due 2025, and the outstanding borrowed shares were reduced by approximately 8,313,000 shares following the consummation of the Exchange.

10-Q filing | 670.2M shares outstanding

10-K filing | 670.0M shares outstanding

10-Q filing | 670.0M shares outstanding

10-Q filing | 669.8M shares outstanding

10-Q filing | 669.8M shares outstanding

10-K filing | 669.8M shares outstanding